← Leaderboards
James H Finke
Cleveland Clinic Foundation
$9,274,196
Attributed
$10,443,465
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $867.1K · FY2005–17$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$10,443,465 · 6
By mechanism
R01$10,443,465 · 6
Top collaborators
- Peter A Cohen5 shared
Most similar at Cleveland Clinic Foundation
Same institution · by research overlap
- Peter A Cohen$9,427,938
- Edward V. Maytin$10,017,085
Others in their field
Top investigators on “Renal Cell Carcinoma”
- David Heimbrook · Leidos Biomedical Research, Inc.$23,387,256
- John H Sampson · Duke University$18,327,278
- William G Kaelin · Dana-Farber Cancer Institute$17,234,468
- M. Celeste Simon · University Of Pennsylvania$15,181,976
- Louis M Weiner · Fox Chase Cancer Center$9,813,757
- Othon Iliopoulos · Dana-Farber Cancer Institute$9,306,791
Research focus
Renal Cell CarcinomaApoptosisT LymphocyteGangliosidesTumorCancer PatientCellsT-LymphocyteIn VitroGene ExpressionMitochondriaNuclear Factor Kappa BetaLeukocyte Activation /TransformationTumor-DerivedTumor ImmunityHuman TissuePeripheral BloodResponseNatural ImmunosuppressionPathway InteractionsCell PhysiologyProgramsMediatingImmune Response
Grant awards (32)
Regulation of MDSC function and trafficking$376,829
R01 · FY2017 · CA · contact PI
Regulation of MDSC function and trafficking$376,829
R01 · FY2016 · CA · contact PI
Regulation of MDSC function and trafficking$376,829
R01 · FY2015 · CA · contact PI
Sunitinib Modulation of Cancer Immunotherapy$501,600
R01 · FY2014 · CA · contact PI
Regulation of MDSC function and trafficking$365,525
R01 · FY2014 · CA · contact PI
Sunitinib Modulation of Cancer Immunotherapy$491,332
R01 · FY2013 · CA · contact PI
Regulation of MDSC function and trafficking$375,343
R01 · FY2013 · CA · contact PI
Sunitinib Modulation of Cancer Immunotherapy$528,446
R01 · FY2012 · CA · contact PI
Sunitinib Modulation of Cancer Immunotherapy$548,705
R01 · FY2011 · CA · contact PI
Sunitinib Modulation of Cancer Immunotherapy$268,456
R01 · FY2010 · CA · contact PI
Tumor Induced Dysregulation of T Cell Immunity$261,383
R01 · FY2010 · CA · contact PI
Tumor Induced Dysregulation of T Cell Immunity$261,665
R01 · FY2009 · CA · contact PI
Tumor Induced Dysregulation of T Cell Immunity$261,665
R01 · FY2008 · CA · contact PI
T Cell Unresponsiveness in Human Tumors$306,828
R01 · FY2007 · CA · contact PI
Tumor Induced Dysregulation of T Cell Immunity$261,799
R01 · FY2007 · CA · contact PI
T Cell Unresponsiveness in Human Tumors$315,991
R01 · FY2006 · CA · contact PI
Tumor Induced Dysregulation of T Cell Immunity$279,427
R01 · FY2006 · CA · contact PI
T Cell Unresponsiveness in Human Tumors$323,595
R01 · FY2005 · CA
Ganglioside Regulation of NFkbeta and Apoptosis$285,728
R01 · FY2005 · CA
T Cell Unresponsiveness in Human Tumors$323,595
R01 · FY2004 · CA
Ganglioside Regulation of NFkbeta and Apoptosis$285,728
R01 · FY2004 · CA
T Cell Unresponsiveness in Human Tumors$323,595
R01 · FY2003 · CA
NFKB DEFECT AND APOPTOSIS IN T CELLS OF CANCER PATIENTS$299,700
R01 · FY2003 · CA
Ganglioside Regulation of NFkbeta and Apoptosis$276,390
R01 · FY2003 · CA
NFKB DEFECT AND APOPTOSIS IN T CELLS OF CANCER PATIENTS$299,700
R01 · FY2002 · CA
Ganglioside Regulation of NFkbeta and Apoptosis$276,390
R01 · FY2002 · CA
T CELL UNRESPONSIVENESS IN HUMAN TUMORS$245,273
R01 · FY2002 · CA
NFKB DEFECT AND APOPTOSIS IN T CELLS OF CANCER PATIENTS$299,700
R01 · FY2001 · CA
Ganglioside Regulation of NFkbeta and Apoptosis$276,390
R01 · FY2001 · CA
T CELL UNRESPONSIVENESS IN HUMAN TUMORS$238,132
R01 · FY2001 · CA
NFKB DEFECT AND APOPTOSIS IN T CELLS OF CANCER PATIENTS$299,700
R01 · FY2000 · CA
T CELL UNRESPONSIVENESS IN HUMAN TUMORS$231,197
R01 · FY2000 · CA